Skip to main content

Table 1 Characteristics of included studies

From: Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials

Author Country Year Design Duration (month) n Drugs (mg) Age (mean) M (%) HT
(%)
DM
(%)
CKD (%) CVD (%)
Doehner[37] England 2002 2-Arm cross-over 0.5 16 Allopurinol (300)—placebo/no ULT 68.5 100 N/A N/A N/A 100
Siu[38] China 2006 2-Arm parallel 12.0 51 Allopurinol (200)—placebo/no ULT 48.3 42.4 78.4 25.5 100.0 N/A
Ogino[56] Japan 2010 2-Arm cross-over 1.9 14 Benzbromarone (100)—placebo/no ULT 60.0 71.4 21.4 N/A N/A 100
Kanbay[39] Turkey 2011 3-Arm parallel 4.0 67 Allopurinol (300)—placebo/no ULT 52.9 51 N/A N/A N/A N/A
Jalalzadeh[57] Iran 2012 2-Arm cross-over 3.0 55 Allopurinol (100)—placebo/no ULT 55.9 62.3 100.0 N/A 100.0 N/A
Ejaz[26] USA 2013 2-Arm parallel 0.2 26 Rasburicase (7.5)—placebo/no ULT 62.4 69.2 100 30.8 100.0 34.7
Sezai[58] Japan 2013 2-Arm parallel 6.0 141 Febuxostat (60)—allopurinol (300) 66.9 82.1 80.7 36.4 77.9 100
Taheraghdam[59] Iran 2014 2-Arm parallel 3.0 65 Allopurinol (200)—placebo/no ULT 69.1 36.0 36.0 63.5 N/A 41.5
Goicoechea[41] Spain 2015 2-Arm parallel 84.0 113 Allopurinol (100)—placebo/no ULT 71.8 N/A N/A N/A 100.0 33.1
Liu[60] China 2015 2-Arm parallel 36.0 176 Allopurinol (100)—placebo/no ULT 50.5 48.3 N/A N/A N/A N/A
Sircar[61] India 2015 2-Arm parallel 6.0 108 Febuxostat (40)—placebo/no ULT 57.3 70.5 98 37.5 100.0 37.5
Takir[62] Turkey 2015 3-Arm parallel 3.0 73 Allopurinol (300)—placebo/no ULT 51.1 49.2 54.7 N/A N/A N/A
Nakagomi[63] Japan 2015 2-Arm parallel 12.0 61 Febuxostat (40)—allopurinol (300) 70.6 69.5 93.7 34.4 N/A N/A
Tani[64] Japan 2015 2-Arm parallel 6.0 60 Febuxostat (10)—placebo/no ULT 68.0 93.5 100.0 31.5 43.5 31.5
Tsuruta[65] Japan 2015 2-Arm parallel 0.9 54 Febuxostat (10)—placebo/no ULT 68.3 64.2 79.3 41.4 100.0 58.5
Beddhu[66] USA 2016 2-Arm parallel 5.6 80 Febuxostat (80)—placebo/no ULT 63.5 35 77.5 100.0 100.0 36.3
Kojima[67] Japan 2016 2-Arm cross-over 0.9 14 Benzbromarone (400)—allopurinol (25) 70.0 71.0 100 N/A N/A N/A
Golmohammadi[68] Iran 2017 2-Arm parallel 12.0 196 Allopurinol (100)—placebo/no ULT N/A 54.6 60.7 40.3 100 N/A
McMullan[69] USA 2017 3-Arm parallel 1.9 149 Probenecid (500)—allopurinol (300)—placebo/no ULT 40.4 49.7 N/A N/A N/A N/A
Jalal[70] USA 2017 2-Arm parallel 2.8 80 Allopurinol (300)—placebo/no ULT 57.4 80 N/A 61.0 100 45.1
Kimura[27] Japan 2018 2-Arm parallel 25.2 441 Febuxostat (40)—placebo/no ULT 65.4 77.3 34.9 48.0 100 21.8
Mukri[29] Malaysia 2018 2-Arm parallel 6.0 100 Febuxostat (40)—placebo/no ULT 65.5 53.5 46.5 N/A 100 30
Kojima[28] Japan 2019 2-Arm parallel 36.0 1070 Febuxostat (40)—allopurinol 75.7 69.4 94.1 37.0 66.1 25.7
  1. CKD Chronic kidney disease, CVD Cardiovascular disease, DM Diabetes mellitus, HT Hypertension, M Male, n Number of participants, N/A Not available, ULT Urate-lowering therapy, USA United States of America